Three biopharma companies recently shuttered their clinical programs after either their drug compounds failed clinical trials or interim futility analysis suggested they were unlikely to meet their clinical endpoints.

Novartis released promising interim Phase II data of iptacopan in C3 glomerulopathy (C3G) at the virtual American Society of Nephrology 2020 Annual Meeting.

Researchers at Johns Hopkins Medicine identified a protein – known as factor D – that appears essential to the inflammatory process of SARS-CoV-2, the virus that causes Covid-19.

Topline results from a 28-week Phase IIb trial show that lenabasum, a novel oral small molecule developed by Massachusetts-based Corbus Pharmaceuticals, did not reduce the rate of new pulmonary exacerbations compared with placebo in patients with cystic fibrosis (CF).

Javelin Biotech announced a three-year collaboration with Pfizer to design and build what could potentially be an industry-leading platform to evaluate ADME (absorption, distribution, metabolism and excretion) properties of small molecules.

iBio Inc. is developing a decoy molecule as a therapeutic against SARS-CoV-2.

Hexagon Bio, a California-based biotechnology company turning nature’s DNA into medicines for cancers and infectious diseases with unmet needs, will move into clinical research with $47 million in Series A financing.  

Seattle Genetics’ shares rocketed after news broke of Merck making a major investment into the Bothwell, Washington-based company via two strategic oncology deals.

Norwood, Massachusetts-based Corbus Pharmaceuticals’ shares plunged 77% at news the company’s lenabasum failed to hit the primary endpoint in the Phase III RESOLVE-1 trial of diffuse cutaneous systemic sclerosis (SSc).

Framingham, Massachusetts-based Alzheon was awarded a $47 million grant over five years from the U.S. National Institute on Aging (NIA), part of the National Institutes of Health, to assist with a Phase III clinical trial of ALZ-801.